Markers of inflammation in women on different hormone replacement therapies

Annals of Medicine

Volumn 35, Issue 5, 2003, Pages 353-361

  Fröhlich, Margit ^a,b   Mühlberger, Nikolai ^c   Hanke, Hartmut ^a   Imhof, Armin ^a   Döring, Angela ^c   Pepys, Mark B ^d   Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

C reactive protein; Coronary disease; Fibrinogen; Hormone replacement therapy; Inflammation; Plasma viscosity

Indexed keywords

C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; FIBRINOGEN; LEVONORGESTREL; NORETHISTERONE ACETATE; PROGESTERONE; SERUM ALBUMIN;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MONOTHERAPY; PLASMA VISCOSITY; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 18144454011     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890310007090     Document Type: Article

References (69)

1. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-7.
2. Chae CU, Ridker PM, Manson JE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost 1997; 78: 770-80.
3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
4. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000; 343: 522-9.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-33.
6. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3.
7. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.
8. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
9. Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation 1992; 86 (suppl. III): 95-9.
10. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
11. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk or myocardial infarction of sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
12. Eriksson M, Egberg N, Wamala S, Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K. Relationship between plasma fibrinogen and coronary heart disease in women. Arterioscler Thromb Vase Biol 1999; 19: 67-72.
13. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-63.
14. Cucuianu M, Plesca L, Bodizs G, Colhon D, Brudasca I. Acute phase reaction and the hemostatic balance. Rev Roum Med Int 1996; 34: 13-8.
15. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-6.
16. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-7.
17. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
18. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996; 144: 537-47.
19. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
20. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988; 58: 249-61.
21. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
22. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999; 19: 893-9.
23. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-6.
24. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999; 100: 717-22.
25. Fröhlich M, Döring A, Imhof A, Pepys MB, Koenig W. Oral contraceptive use is associated with a systemic acute phase response. Fibrinolysis and Proteolysis 1999; 13: 239-44.
26. Fröhlich M, Schunkert H, Hense H-W, Tropitzsch A, Hendricks P, Döring A, et al. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. Br J Haematol 1998; 100: 577-81.
27. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. for the Atherosclerosis Risk in Communities study investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-75.
28. Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994; 71: 420-3.
29. Rosenson RS, Tangney CC, Mosca LJ. Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women. Arterioscler Thromb Vasc Biol 1998; 18: 1902-5.
30. Meilahn EN. Hemostatic factors and risk of cardiovascular disease in women. An overview. Arch Pathol Lab Med 1992; 116: 1313-7.
31. World Health Organisation Principal Investigators (prepared by H. Tunstall-Pedoe). The World Health Organization MONICA Project: a major international collaboration. J Clin Epidemiol 1988; 34: 105-14.
32. WHO MONICA Project (prepared by S. Boethig). WHO MONICA Project: objectives and design. Int J Epidemiol 1989; 18 (suppl. 1): 29-37.
33. Kirkendall WM, Feinleib M, Mark AL. American Heart Association recommendations for human blood pressure determination by sphygmomanometer. Circulation 1980; 62: 1146-55.
34. Cairns V, Keil U, Kleinbaum D, Döring A, Stieber J. Alcohol consumption as a risk factor for high blood pressure: Munich Blood Pressure Study. Hypertension 1984; 6: 124-31.
35. Harkness J. A new method for the measurement of plasma viscosity. Lancet 1963; 2: 280-1.
36. Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: Age-related values in the adult general population. Clin Chem 2000; 46: 934-8.
37. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1952; 18: 499-502.
38. Kuhl H. Effects of progestagens on haemostasis. Maturitas 1996; 24: 1-19.
39. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-25.
40. Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in Retinoid-Placebo Trial in healthy women. Circulation 2002; 106: 1224-28.
41. Sattar N, Perera M, Small M, Lumsden M-A. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet 1999; 354: 487-8.
42. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
43. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
44. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386-92.
45. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145: 375-9.
46. Pepys MB, Rowe IF, Baltz ML. C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol 1985; 27: 83-111.
47. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages. Implications for atherosclerosis. Circulation 2001; 103: 1194-7.
48. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo: Assessment by measuring circulating complement-C-reactive protein-complexes. J Immunol 1996; 157: 473-9.
49. Bhakdi S, Torzewski M, Kouche M, Hemmes M. Complement and atherogenesis. Binding of CRP to degraded, non-oxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348-54.
50. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-41.
51. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
52. Lowe GDO. Rheological influences on thrombosis. In: Meade TW ed., Baillière's Clinical Haematology 1994; 7: 573-91.
53. The writing group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996; 75: 476-80.
54. Marchesoni D, Fiscon D, Bologna A, Dal Pozzo M, Dal Magro L, Mozzanega B. Transdermal estrogen therapy in menopause. Eighteen months follow-up. Clin Exp Obst Gyn 1991, 18: 281-5.
55. Ernst E, Koenig W. Fibrinogen and cardiovascular risk. Vasc Med 1997; 2: 115-25.
56. Sweetnam PM, Thomas HF, Yarnell JW, Beswick AD, Baker IA, Elwood PC. Fibrinogen, viscosity and the 10-year incidence of ischemic heart disease: the Caerphilly and Speedwell Studies. Eur Heart J 1996; 17: 1814-20.
57. Gevers Leuven JA. Sex steroids and lipoprotein metabolism. Pharmac Ther 1994; 64: 99-126.
58. Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin M, Reznikov S. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J Clin Endocrinol Metab 1991; 73: 275-80.
59. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-90.
60. Pepys MB, Dash AC, Markham RE, Thomas HC, Williams BD, Petrie A. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol 1978; 32: 119-24.
61. Nelson SR, Tennent GA, Sethi D, Gower PE, Ballardie FW, Amatayakul-Chantler S, et al. Serum amyloid P component in chronic renal failure and dialysis. Clin Chim Acta 1991; 200: 191-200.
62. Coe JE, Ross MJ. Hamster female protein. A divergent acute phase protein in male and female Syrian hamsters. J Exp Med 1983; 157: 1421-33.
63. Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci 1991; 88: 5134-8.
64. Herrington DM, Brosnihan KB. Effects of estrogen versus droloxifene on adhesion molecules and cytokines in healthy postmenopausal women. J Am Coll Cardiol 1999; 33 (Suppl. 1): A911-2.
65. Seljefiot I, Arnesen H, Hofstad AE, Os I. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemost 2000; 83: 944-8.
66. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
67. Zanger D, Yang BK, Ardans J, Waclawiw MA, Csako G, Wahl LM, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000; 36: 1797-802.
68. De Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women. A 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999; 19: 2993-3000.
69. Rödström K, Bengtsson C, Lissner L, Björkelund C. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden. BMJ 1999; 319: 890-3.